Solubility of a New Cardioactive Prototype Drug in Ionic Liquids

Abstract : Solubility in different solvents is an intrinsic material characteristic for a defined molecule. The solubility of a new cardioactive prototype drug, 3,4-methylenedioxybenzoyl-2-thienylhydrazone (LASSBio-294), was determined in seven different imidazolium based ionic liquids (ILs). The ionic liquids selected were 1-ethyl-3-methylimidazolium methyl phosphonate; 1-ethyl-3-methylimidazolium ethyl phosphonate; 1-ethyl-3-methylimidazolium acetate; 1,3-dimethylimidazolium methyl phosphonate; 1-butyl-3-methylimidazoilium acetate; 1-butyl-3-methylimidazolium tetrafluoroborate; and 1-butyl-3-methylimidazolium bis(trifluoromethane-sulfonyl)imide. In addition, solubility data of LASSBio-294 in water and in mixtures of water and ILs were also measured. For all solvents, the concentration of drug in saturated solutions was determined by high performance liquid chromatography (HPLC). Solid liquid equilibrium measurements were performed in a range of temperatures from 288.15 K to 308.15 K, at atmospheric pressure. From the solubility data it can be concluded that the drug showed sufficient solubility in five of the tested ILs so that these compounds can be suitable for further crystallization studies. The aim of this work is also to discuss and understand the solubility of LASSBio-294 in these alternative solvents. The results indicate that the solubility of the drug is dependent on IL structural variations (cation anion combinations).
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Mines Albi Ecole Nationale Supérieure Des Mines d'Albi-Carmaux <>
Soumis le : vendredi 6 octobre 2017 - 13:32:52
Dernière modification le : jeudi 11 janvier 2018 - 06:25:40




Jacqueline Resende Azevedo, Jean‐jacques Letourneau, Fabienne Espitalier, Maria Inês Ré. Solubility of a New Cardioactive Prototype Drug in Ionic Liquids. Journal of Chemical and Engineering Data, American Chemical Society, 2014, 59 (6), p. 1766-1773. 〈〉. 〈10.1021/je4009624〉. 〈hal-01612003〉



Consultations de la notice